The US Food and Drug Administration (FDA) has approved Janssen Therapeutics' NS3/4A protease inhibitor 'Olysio (simeprevir)' for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with ...
Janssen Therapeutics has obtained accelerated approval from FDA for Sirturo (bedaquiline) tablets as part of combination therapy to treat adult patients with pulmonary multi-drug resistant tuberculosis (MDR-TB). The surrogate endpoint of ...
Tags: Janssen Therapeutics, accelerated approval, FDA, Sirturo tablets